{"success":true,"data":{"pressRelease":{"id":"168642","rtpr_id":"nBw9RJpJNa-20261014","ticker":"ZLAB","exchange":"NASDAQ","all_tickers":["ZLAB","9688"],"title":"Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases","author":"Business Wire","published_at":"2026-10-14T11:00:00.471Z","article_body":"Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an\nIL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases\n\n- Findings from healthy volunteers in the Phase 1/1b trial will be shared at\nACAAI 2026 Annual Scientific Meeting\n\n- Previous non-clinical studies demonstrated the potential for ZL-1503 to\nprovide rapid itch relief and reduce inflammation in atopic diseases\n\n- Investor conference call and webcast to discuss data being presented at\nACAAI and clinical trial plans scheduled for Friday, November 13 at 8:00 a.m.\nET / 9:00 p.m. HKT\n\nZai Lab Limited\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.zailaboratory.com&esheet=54621317&newsitemid=20261014931547&lan=en-US&anchor=Zai+Lab+Limited&index=1&md5=203519eda37d44ad996cb0b647d574b5)\n(NASDAQ: ZLAB; HKEX: 9688) today announced that data from the first clinical\ntrial evaluating ZL-1503, the company’s internally developed interleukin-13\n(IL-13) and interleukin-31 (IL-31)Rα bispecific antibody, will be shared for\nthe first time at the American College of Allergy, Asthma & Immunology\n(ACAAI) 2026 Annual Scientific Meeting, taking place November 12-16, 2026, in\nPhoenix, AZ.\n\n“Atopic dermatitis and other IL-13- and IL-31-driven diseases can severely\nimpact patients’ health and quality of life,” said Rafael G. Amado, M.D.,\nPresident, Head of Global Research and Development at Zai Lab.\n“Preclinically, ZL-1503 has shown the potential to provide relief of\npruritus and inflammation in atopic diseases with less frequent dosing than\nother biologic therapies. We look forward to sharing results from the healthy\nvolunteers’ study cohort evaluating this bispecific antibody with the\nimmunology community at ACAAI.”\n\nZL-1503 is a novel, long-acting, potentially first-in-class treatment for\nmoderate-to-severe atopic dermatitis and other IL-13- and IL-31-driven\ndiseases. IL-13 and IL-31 are key mediators in atopic disease (AD). IL-13\npromotes Type 2 inflammation and tissue changes, while IL-31 drives itch and\namplifies local immune responses. Together, these cytokines perpetuate the\nitch-scratch-inflammation cycle that contributes to the development and\npersistence of atopic dermatitis and related conditions. Zai Lab engineered\nZL-1503 to disrupt this cycle by simultaneously blocking both IL-13 and IL-31\nreceptor-mediated signaling. Preclinical data\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-preclinical-data-suggesting-zl-1503-il-13il&esheet=54621317&newsitemid=20261014931547&lan=en-US&anchor=Preclinical+data&index=2&md5=15e202d4ef3651b35a235390239d6196)\npresented earlier this year showed that ZL-1503 provided rapid itch relief and\nsignificantly reduced inflammation in animal models of atopic diseases.\n\nFindings from the Phase 1/1b first-in-human trial in healthy volunteers\n(NCT07235384) to be shared at ACAAI 2026 will include pharmacokinetic data\nfollowing single-dose administration, as well as pharmacodynamic data on\nAD-related biomarkers across a range of ZL-1503 doses. The ACAAI presentation\nwill also include initial safety and immunogenicity data.\n\nACAAI 2026 ZL-1503 poster details:\n\nTitle: First-in-Human, Single Ascending Dose Study of ZL-1503, a\nHalf-Life-Extended Anti-IL-13/IL-31Ra Bispecific Antibody, in Healthy\nVolunteers\n\nDate/Time: Friday, November 13, 2026; 2:50 p.m. Mountain Time\n\nePoster ID: R376\n\nAbstract Number: 8201\n\nDetails regarding the webcast and conference call are as follows:\n\nDate/Time: Friday, November 13, 2026, at 5:00 a.m. PT / 8:00 a.m. ET / 9:00\np.m. HKT\n\nRegistration available at:\n\nWebcast presentation (preferred): https://edge.media-server.com/mmc/p/a7xzskym\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fedge.media-server.com%2Fmmc%2Fp%2Fa7xzskym&esheet=54621317&newsitemid=20261014931547&lan=en-US&anchor=https%3A%2F%2Fedge.media-server.com%2Fmmc%2Fp%2Fa7xzskym&index=3&md5=e29cf4920311f4103b3828f38b12942d)\n\nDial-in:\nhttps://register-conf.media-server.com/register/BI3cdc6b1d6502458aaafbca52f735d28d\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fregister-conf.media-server.com%2Fregister%2FBI3cdc6b1d6502458aaafbca52f735d28d&esheet=54621317&newsitemid=20261014931547&lan=en-US&anchor=https%3A%2F%2Fregister-conf.media-server.com%2Fregister%2FBI3cdc6b1d6502458aaafbca52f735d28d&index=4&md5=585bd9f7533323bc3d58e91d04bee87c)\n\nPresenters: Rafael G. Amado, M.D., President, Head of Global Research and\nDevelopment, Zai Lab\n\nAbout Zai Lab\n\nZai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based,\ncommercial-stage biopharmaceutical company based in China and the United\nStates. We are focused on discovering, developing, and commercializing\ninnovative products that address medical conditions with significant unmet\nneeds in the areas of oncology, immunology, neuroscience, and infectious\ndisease. Our goal is to leverage our competencies and resources to positively\nimpact human health.\n\nFor additional information about Zai Lab, please visit www.zailaboratory.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.zailaboratory.com&esheet=54621317&newsitemid=20261014931547&lan=en-US&anchor=www.zailaboratory.com&index=5&md5=be2282f7e378f29a02bc419ab0faa1a5)\nor follow us at www.linkedin.com/company/zai-lab\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fzai-lab&esheet=54621317&newsitemid=20261014931547&lan=en-US&anchor=www.linkedin.com%2Fcompany%2Fzai-lab&index=6&md5=210a2a80b15899a3e7bc9fbb71e3f61d)\nor https://x.com/ZaiLab_Global\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2FZaiLab_Global&esheet=54621317&newsitemid=20261014931547&lan=en-US&anchor=https%3A%2F%2Fx.com%2FZaiLab_Global&index=7&md5=d7ce56fee13083253dab75636e26db11)\n.\n\nZai Lab Forward-Looking Statements\n\nThis press release contains forward-looking statements relating to our future\nexpectations, plans, and prospects, for Zai Lab, including, without\nlimitation, statements relating to our prospects and plans for developing and\ncommercializing ZL-1503, and the potential treatment of atopic dermatitis and\nother type 2 helper T-cell (TH2)-driven diseases. All statements, other than\nstatements of historical fact, included in this press release are\nforward-looking statements, and can be identified by words such as “aim,”\n“anticipate,” “believe,” “could,” “estimate,” “expect,”\n“forecast,” “goal,” “intend,” “may,” “plan,”\n“possible,” “potential,” “will,” “would,” and other similar\nexpressions. Such statements constitute forward-looking statements within the\nmeaning of the Private Securities Litigation Reform Act of 1995.\nForward-looking statements are not guarantees or assurances of future\nperformance. Forward-looking statements are based on our expectations and\nassumptions as of the date of this press release and are subject to inherent\nuncertainties, risks and changes in circumstances that may differ materially\nfrom those contemplated by the forward-looking statements. We may not actually\nachieve the plans, carry out the intentions or meet the expectations or\nprojections disclosed in our forward-looking statements, and you should not\nplace undue reliance on these forward-looking statements. Actual results may\ndiffer materially from those indicated by forward-looking statements as a\nresult of various important factors, including but not limited to (1) our\nability to successfully commercialize and generate revenue from our approved\nproducts, (2) our ability to obtain funding for our operations and business\ninitiatives, (3) the results of our clinical and pre-clinical development of\nour product candidates, (4) the content and timing of decisions made by the\nrelevant regulatory authorities regarding regulatory approvals of our product\ncandidates, (5) risks related to doing business in China, and (6) other\nfactors identified in our most recent annual and quarterly reports and in\nother reports we have filed with the U.S. Securities and Exchange Commission\n(SEC). We anticipate that subsequent events and developments will cause our\nexpectations and assumptions to change, and we undertake no obligation to\nupdate or revise any forward-looking statements, whether as a result of new\ninformation, future events, or otherwise, except as may be required by law.\nThese forward-looking statements should not be relied upon as representing our\nviews as of any date subsequent to the date of this press release.\n\nOur SEC filings can be found on our website at www.zailaboratory.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.zailaboratory.com&esheet=54621317&newsitemid=20261014931547&lan=en-US&anchor=www.zailaboratory.com&index=8&md5=df0ee92b61f4c35586d9ebfade40731b)\nand on the SEC’s website at www.SEC.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.SEC.gov&esheet=54621317&newsitemid=20261014931547&lan=en-US&anchor=www.SEC.gov&index=9&md5=1f400dcc65bde6430626ff1a767a596f)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261014931547/en/\n(https://www.businesswire.com/news/home/20261014931547/en/)\n\nFor more information, please contact:\n\n\n\nInvestor Relations: \n\nChristine Chiou / Cyan Liu\n\n+1 (917) 886-6929 / +86 195 3130 8895\n\nchristine.chiou1@zailaboratory.com (mailto:christine.chiou1@zailaboratory.com)\n/ cyan.liu@zailaboratory.com \n(mailto:cyan.liu@zailaboratory.com) \n\n\nMedia: \n\nShaun Maccoun / Xiaoyu Chen\n\n+1 (857) 270-8854 / +86 185 0015 5011\n\nshaun.maccoun@zailaboratory.com (mailto:shaun.maccoun@zailaboratory.com) /\nxiaoyu.chen@zailaboratory.com (mailto:xiaoyu.chen@zailaboratory.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw9RJpJNa-20261014","title":"Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases","author":"Business Wire","ticker":"ZLAB","created":"2026-10-14T11:00:00.471Z","tickers":["ZLAB","9688"],"exchange":"NASDAQ","article_body":"Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an\nIL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases\n\n- Findings from healthy volunteers in the Phase 1/1b trial will be shared at\nACAAI 2026 Annual Scientific Meeting\n\n- Previous non-clinical studies demonstrated the potential for ZL-1503 to\nprovide rapid itch relief and reduce inflammation in atopic diseases\n\n- Investor conference call and webcast to discuss data being presented at\nACAAI and clinical trial plans scheduled for Friday, November 13 at 8:00 a.m.\nET / 9:00 p.m. HKT\n\nZai Lab Limited\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.zailaboratory.com&esheet=54621317&newsitemid=20261014931547&lan=en-US&anchor=Zai+Lab+Limited&index=1&md5=203519eda37d44ad996cb0b647d574b5)\n(NASDAQ: ZLAB; HKEX: 9688) today announced that data from the first clinical\ntrial evaluating ZL-1503, the company’s internally developed interleukin-13\n(IL-13) and interleukin-31 (IL-31)Rα bispecific antibody, will be shared for\nthe first time at the American College of Allergy, Asthma & Immunology\n(ACAAI) 2026 Annual Scientific Meeting, taking place November 12-16, 2026, in\nPhoenix, AZ.\n\n“Atopic dermatitis and other IL-13- and IL-31-driven diseases can severely\nimpact patients’ health and quality of life,” said Rafael G. Amado, M.D.,\nPresident, Head of Global Research and Development at Zai Lab.\n“Preclinically, ZL-1503 has shown the potential to provide relief of\npruritus and inflammation in atopic diseases with less frequent dosing than\nother biologic therapies. We look forward to sharing results from the healthy\nvolunteers’ study cohort evaluating this bispecific antibody with the\nimmunology community at ACAAI.”\n\nZL-1503 is a novel, long-acting, potentially first-in-class treatment for\nmoderate-to-severe atopic dermatitis and other IL-13- and IL-31-driven\ndiseases. IL-13 and IL-31 are key mediators in atopic disease (AD). IL-13\npromotes Type 2 inflammation and tissue changes, while IL-31 drives itch and\namplifies local immune responses. Together, these cytokines perpetuate the\nitch-scratch-inflammation cycle that contributes to the development and\npersistence of atopic dermatitis and related conditions. Zai Lab engineered\nZL-1503 to disrupt this cycle by simultaneously blocking both IL-13 and IL-31\nreceptor-mediated signaling. Preclinical data\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-preclinical-data-suggesting-zl-1503-il-13il&esheet=54621317&newsitemid=20261014931547&lan=en-US&anchor=Preclinical+data&index=2&md5=15e202d4ef3651b35a235390239d6196)\npresented earlier this year showed that ZL-1503 provided rapid itch relief and\nsignificantly reduced inflammation in animal models of atopic diseases.\n\nFindings from the Phase 1/1b first-in-human trial in healthy volunteers\n(NCT07235384) to be shared at ACAAI 2026 will include pharmacokinetic data\nfollowing single-dose administration, as well as pharmacodynamic data on\nAD-related biomarkers across a range of ZL-1503 doses. The ACAAI presentation\nwill also include initial safety and immunogenicity data.\n\nACAAI 2026 ZL-1503 poster details:\n\nTitle: First-in-Human, Single Ascending Dose Study of ZL-1503, a\nHalf-Life-Extended Anti-IL-13/IL-31Ra Bispecific Antibody, in Healthy\nVolunteers\n\nDate/Time: Friday, November 13, 2026; 2:50 p.m. Mountain Time\n\nePoster ID: R376\n\nAbstract Number: 8201\n\nDetails regarding the webcast and conference call are as follows:\n\nDate/Time: Friday, November 13, 2026, at 5:00 a.m. PT / 8:00 a.m. ET / 9:00\np.m. HKT\n\nRegistration available at:\n\nWebcast presentation (preferred): https://edge.media-server.com/mmc/p/a7xzskym\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fedge.media-server.com%2Fmmc%2Fp%2Fa7xzskym&esheet=54621317&newsitemid=20261014931547&lan=en-US&anchor=https%3A%2F%2Fedge.media-server.com%2Fmmc%2Fp%2Fa7xzskym&index=3&md5=e29cf4920311f4103b3828f38b12942d)\n\nDial-in:\nhttps://register-conf.media-server.com/register/BI3cdc6b1d6502458aaafbca52f735d28d\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fregister-conf.media-server.com%2Fregister%2FBI3cdc6b1d6502458aaafbca52f735d28d&esheet=54621317&newsitemid=20261014931547&lan=en-US&anchor=https%3A%2F%2Fregister-conf.media-server.com%2Fregister%2FBI3cdc6b1d6502458aaafbca52f735d28d&index=4&md5=585bd9f7533323bc3d58e91d04bee87c)\n\nPresenters: Rafael G. Amado, M.D., President, Head of Global Research and\nDevelopment, Zai Lab\n\nAbout Zai Lab\n\nZai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based,\ncommercial-stage biopharmaceutical company based in China and the United\nStates. We are focused on discovering, developing, and commercializing\ninnovative products that address medical conditions with significant unmet\nneeds in the areas of oncology, immunology, neuroscience, and infectious\ndisease. Our goal is to leverage our competencies and resources to positively\nimpact human health.\n\nFor additional information about Zai Lab, please visit www.zailaboratory.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.zailaboratory.com&esheet=54621317&newsitemid=20261014931547&lan=en-US&anchor=www.zailaboratory.com&index=5&md5=be2282f7e378f29a02bc419ab0faa1a5)\nor follow us at www.linkedin.com/company/zai-lab\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fzai-lab&esheet=54621317&newsitemid=20261014931547&lan=en-US&anchor=www.linkedin.com%2Fcompany%2Fzai-lab&index=6&md5=210a2a80b15899a3e7bc9fbb71e3f61d)\nor https://x.com/ZaiLab_Global\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2FZaiLab_Global&esheet=54621317&newsitemid=20261014931547&lan=en-US&anchor=https%3A%2F%2Fx.com%2FZaiLab_Global&index=7&md5=d7ce56fee13083253dab75636e26db11)\n.\n\nZai Lab Forward-Looking Statements\n\nThis press release contains forward-looking statements relating to our future\nexpectations, plans, and prospects, for Zai Lab, including, without\nlimitation, statements relating to our prospects and plans for developing and\ncommercializing ZL-1503, and the potential treatment of atopic dermatitis and\nother type 2 helper T-cell (TH2)-driven diseases. All statements, other than\nstatements of historical fact, included in this press release are\nforward-looking statements, and can be identified by words such as “aim,”\n“anticipate,” “believe,” “could,” “estimate,” “expect,”\n“forecast,” “goal,” “intend,” “may,” “plan,”\n“possible,” “potential,” “will,” “would,” and other similar\nexpressions. Such statements constitute forward-looking statements within the\nmeaning of the Private Securities Litigation Reform Act of 1995.\nForward-looking statements are not guarantees or assurances of future\nperformance. Forward-looking statements are based on our expectations and\nassumptions as of the date of this press release and are subject to inherent\nuncertainties, risks and changes in circumstances that may differ materially\nfrom those contemplated by the forward-looking statements. We may not actually\nachieve the plans, carry out the intentions or meet the expectations or\nprojections disclosed in our forward-looking statements, and you should not\nplace undue reliance on these forward-looking statements. Actual results may\ndiffer materially from those indicated by forward-looking statements as a\nresult of various important factors, including but not limited to (1) our\nability to successfully commercialize and generate revenue from our approved\nproducts, (2) our ability to obtain funding for our operations and business\ninitiatives, (3) the results of our clinical and pre-clinical development of\nour product candidates, (4) the content and timing of decisions made by the\nrelevant regulatory authorities regarding regulatory approvals of our product\ncandidates, (5) risks related to doing business in China, and (6) other\nfactors identified in our most recent annual and quarterly reports and in\nother reports we have filed with the U.S. Securities and Exchange Commission\n(SEC). We anticipate that subsequent events and developments will cause our\nexpectations and assumptions to change, and we undertake no obligation to\nupdate or revise any forward-looking statements, whether as a result of new\ninformation, future events, or otherwise, except as may be required by law.\nThese forward-looking statements should not be relied upon as representing our\nviews as of any date subsequent to the date of this press release.\n\nOur SEC filings can be found on our website at www.zailaboratory.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.zailaboratory.com&esheet=54621317&newsitemid=20261014931547&lan=en-US&anchor=www.zailaboratory.com&index=8&md5=df0ee92b61f4c35586d9ebfade40731b)\nand on the SEC’s website at www.SEC.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.SEC.gov&esheet=54621317&newsitemid=20261014931547&lan=en-US&anchor=www.SEC.gov&index=9&md5=1f400dcc65bde6430626ff1a767a596f)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261014931547/en/\n(https://www.businesswire.com/news/home/20261014931547/en/)\n\nFor more information, please contact:\n\n\n\nInvestor Relations: \n\nChristine Chiou / Cyan Liu\n\n+1 (917) 886-6929 / +86 195 3130 8895\n\nchristine.chiou1@zailaboratory.com (mailto:christine.chiou1@zailaboratory.com)\n/ cyan.liu@zailaboratory.com \n(mailto:cyan.liu@zailaboratory.com) \n\n\nMedia: \n\nShaun Maccoun / Xiaoyu Chen\n\n+1 (857) 270-8854 / +86 185 0015 5011\n\nshaun.maccoun@zailaboratory.com (mailto:shaun.maccoun@zailaboratory.com) /\nxiaoyu.chen@zailaboratory.com (mailto:xiaoyu.chen@zailaboratory.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-14T11:00:00.57134712Z","server_sent_at_ms":1791975600571},"received_at":"2026-10-14T11:00:00.637Z","source_url":"https://www.businesswire.com/news/home/20261014931547/en/"},"analysis":{"id":"156904","press_release_id":"168642","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Zai Lab will present first clinical trial data for ZL-1503, its internally developed IL-13/IL-31Rα bispecific antibody, at the ACAAI 2026 Annual Scientific Meeting on November 13 in Phoenix.\n\nThe Phase 1/1b first-in-human trial (NCT07235384) in healthy volunteers will show single-dose pharmacokinetics, pharmacodynamic biomarker data, and initial safety and immunogenicity findings.\n\nZL-1503 is positioned as a potentially first-in-class, long-acting treatment for moderate-to-severe atopic dermatitis; the company will host an investor call on November 13 at 8:00 a.m. ET to discuss the data and trial plans.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Data-driven catalyst calendar: watch Nov 13 ACAAI presentation and investor call for first-in-human ZL-1503 PK/safety readout."},"keyFigures":{"drugName":"ZL-1503","phaseOfTrial":"Phase 1/1b","customDimensions":{"trial_registry_id":"NCT07235384","presentation_details":"ACAAI 2026 poster R376, abstract 8201, Nov 13, 2026; investor call Nov 13, 8:00 a.m. ET"}},"quotedText":"Preclinically, ZL-1503 has shown the potential to provide relief of pruritus and inflammation in atopic diseases with less frequent dosing than other biologic therapies.","namedEntities":{"people":[{"name":"Rafael G. Amado, M.D.","role":"President, Head of Global Research and Development"}],"products":["ZL-1503"],"companies":[{"name":"Zai Lab Limited","ticker":"ZLAB","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Announcement that first-in-human Phase 1/1b data for pipeline asset ZL-1503 will be presented at ACAAI 2026; actual data not yet disclosed. Pipeline progress is mildly positive but early-stage and low-impact until results are shown on November 13."},"tickerRelevance":{"others":[],"primary":"ZLAB"},"globalImportance":20,"audienceRelevance":25,"eventTypeSecondary":["other"],"importanceComponents":{"tickerTier":"mid-cap biotech","eventGravity":"pipeline data-announcement (no results yet)","sectorWeight":"biotech pipeline news","earlyStageAsset":true}},"event_type":"clinical_trial","event_type_secondary":["other"],"sentiment":"bullish","material_impact_score":2,"narrative":"Zai Lab will present first clinical trial data for ZL-1503, its internally developed IL-13/IL-31Rα bispecific antibody, at the ACAAI 2026 Annual Scientific Meeting on November 13 in Phoenix.\n\nThe Phase 1/1b first-in-human trial (NCT07235384) in healthy volunteers will show single-dose pharmacokinetics, pharmacodynamic biomarker data, and initial safety and immunogenicity findings.\n\nZL-1503 is positioned as a potentially first-in-class, long-acting treatment for moderate-to-severe atopic dermatitis; the company will host an investor call on November 13 at 8:00 a.m. ET to discuss the data and trial plans.","key_figures":{"drugName":"ZL-1503","phaseOfTrial":"Phase 1/1b","customDimensions":{"trial_registry_id":"NCT07235384","presentation_details":"ACAAI 2026 poster R376, abstract 8201, Nov 13, 2026; investor call Nov 13, 8:00 a.m. ET"}},"named_entities":{"people":[{"name":"Rafael G. Amado, M.D.","role":"President, Head of Global Research and Development"}],"products":["ZL-1503"],"companies":[{"name":"Zai Lab Limited","ticker":"ZLAB","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T11:00:06.471Z","global_importance":20,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap biotech","eventGravity":"pipeline data-announcement (no results yet)","sectorWeight":"biotech pipeline news","earlyStageAsset":true}},"durationMs":5765,"modelName":"glm-5.3-flashx"}}